A phase I study of PankoMab-GEX, a humanised glyco-optimised monoclonal antibody to a novel tumour-specific MUC1 glycopeptide epitope in patients with advanced carcinomas
European Journal of Cancer2016Vol. 63, pp. 55–63
Citations Over TimeTop 10% of 2016 papers
Walter Fiedler, S. DeDosso, Sara Cresta, Jens Weidmann, Anna Tessari, Marc Salzberg, B. Dietrich, Harald Baumeister, Steffen Goletz, Luca Gianni, Cristiana Sessa
Abstract
PankoMab-GEX is safe, well tolerated, and showed promising anti-tumour activity in advanced disease. A phase IIb study is ongoing evaluating the efficacy of PankoMab-GEX as a maintenance therapy in advanced ovarian cancer.
Related Papers
- → Drug tolerability: How much ambiguity can be tolerated? A systematic review of the assessment of tolerability in clinical studies(2021)45 cited
- → Mapping of 10 epitopes on bovine herpesvirus type 1 glycoproteins gl and glll(1990)34 cited
- → Real-World Evaluation of the Tolerability to Onabotulinum Toxin A: The RETO Study(2022)4 cited
- → Induction of High Levels of Antibodies Recognizing the Neutralizing Epitope ELDKWA and the D- or K-Position-Mutated Epitopes by Candidate Epitope Vaccines against HIV-1(2000)7 cited
- Progress on Epitope-Vaccine(2012)